JP2019510078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510078A5 JP2019510078A5 JP2018563405A JP2018563405A JP2019510078A5 JP 2019510078 A5 JP2019510078 A5 JP 2019510078A5 JP 2018563405 A JP2018563405 A JP 2018563405A JP 2018563405 A JP2018563405 A JP 2018563405A JP 2019510078 A5 JP2019510078 A5 JP 2019510078A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- formulation
- antibody
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 72
- 239000012634 fragment Substances 0.000 claims description 28
- 102000004889 Interleukin-6 Human genes 0.000 claims description 27
- 108090001005 Interleukin-6 Proteins 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 10
- 201000011190 diabetic macular edema Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 206010013774 Dry eye Diseases 0.000 claims description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 6
- 206010038848 Retinal detachment Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 229940068977 polysorbate 20 Drugs 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 claims description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022058898A JP2022084922A (ja) | 2016-02-23 | 2022-03-31 | Ｉｌ－６アンタゴニスト製剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298774P | 2016-02-23 | 2016-02-23 | |
| US62/298,774 | 2016-02-23 | ||
| PCT/US2017/019131 WO2017147293A1 (en) | 2016-02-23 | 2017-02-23 | Il-6 antagonist formulations and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058898A Division JP2022084922A (ja) | 2016-02-23 | 2022-03-31 | Ｉｌ－６アンタゴニスト製剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510078A JP2019510078A (ja) | 2019-04-11 |
| JP2019510078A5 true JP2019510078A5 (enExample) | 2020-03-26 |
Family
ID=59685584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563405A Pending JP2019510078A (ja) | 2016-02-23 | 2017-02-23 | Ｉｌ−６アンタゴニスト製剤およびその使用 |
| JP2022058898A Pending JP2022084922A (ja) | 2016-02-23 | 2022-03-31 | Ｉｌ－６アンタゴニスト製剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058898A Pending JP2022084922A (ja) | 2016-02-23 | 2022-03-31 | Ｉｌ－６アンタゴニスト製剤およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190046642A1 (enExample) |
| EP (1) | EP3419599A4 (enExample) |
| JP (2) | JP2019510078A (enExample) |
| KR (1) | KR20180116359A (enExample) |
| CN (1) | CN108718522A (enExample) |
| AR (1) | AR107708A1 (enExample) |
| AU (1) | AU2017223687A1 (enExample) |
| BR (1) | BR112018017031A2 (enExample) |
| CA (1) | CA3012350A1 (enExample) |
| MX (1) | MX2018010032A (enExample) |
| WO (1) | WO2017147293A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3083971A1 (en) * | 2017-11-30 | 2019-06-06 | Bio-Thera Solutions, Ltd. | Liquid formulation of humanized antibody for treating il-6 related diseases |
| CN112739378B (zh) * | 2018-09-14 | 2025-05-06 | 田边三菱制药株式会社 | 含有人抗il-33单克隆抗体的医药用组合物 |
| MA54095A (fr) * | 2018-10-31 | 2022-02-09 | Richter Gedeon Nyrt | Formulations pharmaceutiques aqueuses |
| EP3962942B1 (en) * | 2019-05-01 | 2025-10-22 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
| WO2021168386A1 (en) * | 2020-02-21 | 2021-08-26 | Spitfire Pharma Llc | Glp-1r and gcgr agonists, formulations, and methods of use |
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| KR20230066318A (ko) * | 2020-06-26 | 2023-05-15 | 트레포일 테라퓨틱스, 인크. | 재조합 변형된 섬유모세포 성장 인자 및 이의 치료적 용도 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| CN116261448A (zh) * | 2020-08-19 | 2023-06-13 | 百奥泰生物制药股份有限公司 | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
| JP2023042974A (ja) * | 2021-09-15 | 2023-03-28 | シスメックス株式会社 | 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体 |
| CN116355825A (zh) * | 2022-02-25 | 2023-06-30 | 南京工业大学 | 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法 |
| CN119923252A (zh) * | 2022-09-30 | 2025-05-02 | 索尼特生物治疗公司 | 低剂量il-6制剂及其使用方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| PT1137941E (pt) | 1998-12-10 | 2009-10-15 | Brystol Myers Squibb Company | Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| MXPA04011004A (es) | 2002-05-07 | 2005-01-25 | Control Delivery Sys Inc | Procesos para formar un dispositivo de administracion de farmaco. |
| EP1572103A4 (en) | 2002-11-15 | 2008-02-13 | Centocor Inc | ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| AU2004308482A1 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1966244B1 (en) | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| MX2008014692A (es) | 2006-05-19 | 2009-08-18 | Alder Biopharmaceuticals Inc | Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno. |
| US20080200655A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein Formulations Containing Sorbitol |
| ES2721753T3 (es) | 2007-05-21 | 2019-08-05 | Alderbio Holdings Llc | Anticuerpos contra IL-6 y usos de los mismos |
| WO2009035707A1 (en) * | 2007-09-14 | 2009-03-19 | Acambis Inc. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| US8043620B2 (en) | 2007-11-21 | 2011-10-25 | Amgen Inc. | Wise binding agents and epitopes |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| NZ621174A (en) | 2008-01-15 | 2015-09-25 | Abbvie Deutschland | Powdered protein compositions and methods of making same |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| ES2395231T3 (es) | 2008-09-12 | 2013-02-11 | Kdf Co., Ltd. | Dispositivo de proyección de agua en forma de surtidor |
| WO2010039750A2 (en) * | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) * | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CN102224169A (zh) | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| BRPI1007005A2 (pt) * | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2593142B8 (en) * | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| CA2857194A1 (en) * | 2011-12-07 | 2013-06-13 | Thomas M. Dillon | Igg2 disulfide isoform separation |
| WO2013181495A2 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corporation | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| MX2015003007A (es) | 2012-09-07 | 2015-06-05 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab. |
| BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
| AU2013342163B2 (en) * | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| MX2016000364A (es) * | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| DK4268843T3 (da) * | 2014-11-07 | 2025-11-10 | F Hoffmann La Roche Ltd | Forbedrede IL-6-antistoffer |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2017
- 2017-02-23 US US16/078,671 patent/US20190046642A1/en not_active Abandoned
- 2017-02-23 EP EP17757207.0A patent/EP3419599A4/en active Pending
- 2017-02-23 CA CA3012350A patent/CA3012350A1/en not_active Abandoned
- 2017-02-23 CN CN201780013039.9A patent/CN108718522A/zh active Pending
- 2017-02-23 BR BR112018017031A patent/BR112018017031A2/pt not_active IP Right Cessation
- 2017-02-23 MX MX2018010032A patent/MX2018010032A/es unknown
- 2017-02-23 AU AU2017223687A patent/AU2017223687A1/en not_active Abandoned
- 2017-02-23 KR KR1020187027338A patent/KR20180116359A/ko not_active Withdrawn
- 2017-02-23 JP JP2018563405A patent/JP2019510078A/ja active Pending
- 2017-02-23 AR ARP170100456A patent/AR107708A1/es unknown
- 2017-02-23 WO PCT/US2017/019131 patent/WO2017147293A1/en not_active Ceased
-
2021
- 2021-08-31 US US17/462,654 patent/US12048746B2/en active Active
-
2022
- 2022-03-31 JP JP2022058898A patent/JP2022084922A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510078A5 (enExample) | ||
| US12371481B2 (en) | Methods for treating age-related macular degeneration | |
| AU2021286278B2 (en) | Methods for treating ocular diseases | |
| US20200270342A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta) | |
| JP2016504416A5 (enExample) | ||
| JP2017535285A5 (enExample) | ||
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| JP2018536650A5 (enExample) | ||
| RU2016145136A (ru) | РЕКОМБИНАНТНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА vNAR, НЕЙТРАЛИЗУЮЩИЕ ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ (VEGF) | |
| KR20220062279A (ko) | 안질환의 치료 방법 | |
| WO2018195912A1 (zh) | 一种眼用药物组合物及其用途 | |
| Erichev et al. | Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma | |
| WO2020022438A1 (ja) | 網膜線維化を伴う眼疾患の処置剤 | |
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| RU2771900C2 (ru) | Способ лечения болезней глаз | |
| CN120204358A (zh) | 一种含有抗vegf的融合蛋白的药物组合物 | |
| RU2025109429A (ru) | Прогнозирование ответа на антагонисты il-6 | |
| RU2024102531A (ru) | Состав на основе раствора белка, содержащий антитело к vegf в высокой концентрации | |
| RU2020137402A (ru) | Способы лечения заболевания с использованием забуференных составов бевацизумаба | |
| NZ731090B2 (en) | Improved il-6 antibodies |